XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XOMAP SEC filings page.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) reported $48.6M in revenue over the twelve months to Mar 31, 2026, up 13.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025’s revenue rebound restored operating profit, but weak cash conversion and reduced liquidity show earnings are not arriving evenly as cash.
FY2025 net income was$31.7M , but operating cash flow was only$2.87M , a wide gap that makes accounting profit a poor proxy for cash realization. That is also a shift from operating cash flow of-$13.7M in FY2024, showing the cash profile changed, not merely expanded.
Operating margin moved from
Debt-to-equity fell from 1.7x to 1.1x, reducing leverage relative to FY2024. Current ratio fell from 5.2x to 3.4x, so short-term coverage weakened even as debt leverage improved.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock has an operating margin of 21.8%, meaning the company retains $22 of operating profit per $100 of revenue. Among its peers this margin ranks in the lower range, for a profitability score of 9/100. This is up from -140.3% the prior year.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock's revenue surged 83.1% year-over-year to $52.1M, reflecting rapid business expansion. This strong growth earns a score of 99/100.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock has a moderate D/E ratio of 1.15. This balance of debt and equity financing earns a leverage score of 44/100.
With a current ratio of 3.37, XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock holds $3.37 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 82/100.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock generates a 37.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 19/100. This is up from -22.3% the prior year.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
For every $1 of reported earnings, XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock generates $0.09 in operating cash flow ($2.9M OCF vs $31.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock earns $0.87 in operating income for every $1 of interest expense ($11.4M vs $13.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock generated $12.3M in revenue in Q1 2026. This represents a decrease of 22.6% from the same quarter a year earlier. Against the prior quarter it is down 10.5%.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock reported $4.5M in net income in Q1 2026. This represents an increase of 88.6% from the same quarter a year earlier. Against the prior quarter it is down 26.8%.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock earned $0.17 per diluted share (EPS) in Q1 2026. Against the prior quarter it is down 34.6%.
Not reported for Q1 2026.
Cash & Balance Sheet
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock held $85.6M in cash against $88.8M in long-term debt as of Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock's operating margin was -3.9% in Q1 2026, reflecting core business profitability. This is down 41.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 19.8 percentage points.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock's net profit margin was 36.3% in Q1 2026, showing the share of revenue converted to profit. This is up 21.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.1 percentage points.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock's quarterly ROE was 4.8% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is up 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.5 percentage points.
Not reported for Q1 2026.
Capital Allocation
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock invested $49K in research and development in Q1 2026. This represents a decrease of 96.2% from the same quarter a year earlier. Against the prior quarter it is down 82.6%.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock spent $264K on share buybacks in Q1 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 51.6% from the same quarter a year earlier. Against the prior quarter it is down 98.1%.
Not reported for Q1 2026.
XOMAP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.3M-22.6% | $13.8M+57.9% | $9.4M+29.9% | $13.1M+18.4% | $15.9M+967.9% | $8.7M+375.4% | $7.2M+767.1% | $11.1M+568.6% |
| R&D Expenses | $49K-96.2% | $281K-67.5% | $69K-91.6% | $69K-94.1% | $1.3M+3818.2% | $864K+3356.0% | $817K+3168.0% | $1.2M+2876.9% |
| SG&A Expenses | $11.9M+45.6% | $10.4M+48.9% | $9.7M+21.4% | $7.8M-29.1% | $8.1M-3.7% | $7.0M-3.7% | $8.0M+25.9% | $11.0M+90.5% |
| Operating Income | -$480K-108.1% | $2.2Mn/m | -$1.3Mn/m | $4.6Mn/m | $5.9Mn/m | -$7.3Mn/m | -$15.6Mn/m | -$10.1Mn/m |
| Interest Expense | $3.4M-3.1% | $3.0M-10.8% | $3.3M-5.5% | $3.2M-4.9% | $3.5M-2.4% | $3.4M | $3.5M | $3.4M |
| Income Tax | $1Kn/m | $54Kn/m | $49Kn/m | N/A | $0n/m | -$5.7M | $0 | $0 |
| Net Income | $4.5M+88.6% | $6.1Mn/m | $14.1Mn/m | $9.2M-42.5% | $2.4Mn/m | -$4.0Mn/m | -$17.2Mn/m | $16.0Mn/m |
| EPS (Basic) | $0.18 | $0.27 | $0.74 | $0.46-47.7% | $0.06 | -$0.45n/m | -$1.59n/m | $0.88 |
| EPS (Diluted) | $0.17 | $0.26 | $0.70 | $0.44-47.6% | $0.06 | -$0.45n/m | -$1.59n/m | $0.84 |
| Diluted Shares (Avg) | 17M | N/A | 18M | 18M+2.5% | 18M | N/A | 12M+2.1% | 17M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA.
XOMAP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $271.9M+27.8% | $272.7M+23.2% | $263.2M+17.8% | $223.5M-8.1% | $212.8M-3.0% | $221.3M-5.6% | $223.3M+80.0% | $243.3M+93.6% |
| Current Assets | $118.7M+4.9% | $117.3M-6.6% | $110.7M-30.4% | $104.9M-35.3% | $113.2M-22.9% | $125.6M-25.8% | $159.0M+360.9% | $162.2M+322.2% |
| Cash & Equivalents | $85.6M-5.2% | $82.9M-18.4% | $45.2M-68.2% | $75.1M-47.8% | $90.3M-33.7% | $101.7M-33.7% | $142.1M+324.4% | $143.9M+357.6% |
| Total Liabilities | $159.0M+24.1% | $168.7M+21.1% | $155.2M+12.0% | $131.0M-8.6% | $128.1M-6.5% | $139.4M-4.3% | $138.5M+664.1% | $143.3M+822.2% |
| Current Liabilities | $33.1M+61.9% | $34.8M+42.9% | $28.3M+33.9% | $21.5M+15.5% | $20.4M+31.5% | $24.4M+25.0% | $21.1M+104.5% | $18.6M+162.7% |
| Non-Current Liabilities | $125.9M+16.9% | $133.9M+16.5% | $126.9M+8.1% | $109.5M-12.2% | $107.7M-11.4% | $115.0M-8.8% | $117.4M+1405.9% | $124.7M+1375.4% |
| Long-Term Debt | $88.8M-11.1% | $96.5M-9.8% | $94.4M-12.7% | $102.2M-11.2% | $99.9M-12.7% | $106.9M-9.8% | $108.1M | $115.1M |
| Total Equity | $92.9M+9.7% | $83.9M+35.6% | $87.9M+3.7% | $72.4M-27.6% | $84.6M+2.8% | $61.9M-30.2% | $84.8M-20.0% | $100.0M-9.2% |
| Retained Earnings | -$1.2Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.2Bn/m |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill.
XOMAP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6.1M+178.5% | -$5.5Mn/m | -$296Kn/m | $6.5M+137.3% | $2.2Mn/m | -$2.9Mn/m | -$8.6Mn/m | $2.7Mn/m |
| Stock-Based Compensation | $2.3M+15.0% | N/A | N/A | N/A | $2.0M-30.6% | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $3K | $0 | $0 |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$2.9M | -$8.6M | $2.7M |
| Investing Cash Flow | $6.6Mn/m | $19.3Mn/m | $58.2M+511.4% | -$20.0M-438.9% | -$6.7Mn/m | -$36.4M-761.1% | $9.5M+73.3% | $5.9Mn/m |
| Financing Cash Flow | -$7.6Mn/m | -$10.7Mn/m | -$5.8Mn/m | -$3.0Mn/m | -$6.9Mn/m | -$1.1M-100.9% | -$4.0Mn/m | -$1.1Mn/m |
| Dividends Paid | $1.4M+4.1% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% |
| Share Buybacks | $264K-51.6% | $13.6Mn/m | $25Kn/m | $1.8Mn/m | $545K+4092.3% | $0 | $0 | $0 |
Not reported in any period shown, so not listed: Depreciation & Amortization.
XOMAP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3.9%-41.2pp | 15.9%+99.1pp | -14.2% | 35.1%+126.0pp | 37.3% | -83.2% | -217.3% | -90.9% |
| Net Margin | 36.3%+21.4pp | 44.4%+89.9pp | 150.3% | 70.0% | 14.9% | -45.5% | -239.6% | 144.2% |
| Return on Equity | 4.8%+2.0pp | 7.3%+13.7pp | 16.0%+36.3pp | 12.7%-3.3pp | 2.8%+13.2pp | -6.4%+16.3pp | -20.3%-15.1pp | 16.0%+20.9pp |
| Return on Assets | 1.6%+0.5pp | 2.2%+4.0pp | 5.3%+13.1pp | 4.1%-2.5pp | 1.1%+5.0pp | -1.8%+6.8pp | -7.7%-3.3pp | 6.6%+10.9pp |
| Current Ratio | 3.59-2.0x | 3.37-1.8x | 3.91-3.6x | 4.88-3.8x | 5.54-3.9x | 5.15-3.5x | 7.52+4.2x | 8.71+3.3x |
| Debt-to-Equity | 0.96-0.2x | 1.15-0.6x | 1.07-0.2x | 1.41+0.3x | 1.18-0.2x | 1.73+0.4x | 1.27 | 1.15 |
| Liabilities-to-Equity | 1.71+0.2x | 2.01-0.2x | 1.76+0.1x | 1.81+0.4x | 1.51-0.2x | 2.25+0.6x | 1.63+1.5x | 1.43+1.3x |
| Asset Turnover | 0.050.0x | 0.050.0x | 0.040.0x | 0.060.0x | 0.07+0.1x | 0.040.0x | 0.030.0x | 0.050.0x |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -33.4% | -119.8% | 24.6% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock XOMAP | FY2025 | $52.1M | $31.7M | 60.8% | N/A | 43/100 |
| Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP | FY2025 | $63.3M | $6.8M | 10.8% | N/A | 28/100 |
| Ligand Pharmaceuticals Inc. LGND | FY2025 | $268.1M | $124.5M | 46.4% | $6.3B | 70/100 |
| Royalty Pharma plc RPRX | FY2025 | $2.4B | $770.9M | 32.4% | $38.8B | 52/100 |
| Halozyme Therapeutics, Inc. HALO | FY2025 | $1.4B | $316.9M | 22.7% | $14.8B | 78/100 |
| AbCellera Biologics Inc. ABCL | FY2025 | $75.1M | -$146.4M | N/A | $4.0B | 53/100 |
Where XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock Ranks
Frequently Asked Questions
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) reported $52.1M in total revenue for fiscal year 2025. This represents a 83.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) revenue grew by 83.1% year-over-year, from $28.5M to $52.1M in fiscal year 2025.
Yes, XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) reported a net income of $33.8M over the trailing 12 months to March 31, 2026. In fiscal year 2025 it reported a net income of $31.7M, with a net profit margin of 60.8%.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) reported diluted earnings per share of $1.46 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
As of fiscal year 2025, XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) had $82.9M in cash and equivalents against $96.5M in long-term debt.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) had an operating margin of 21.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) had a net profit margin of 60.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) has a return on equity of 37.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) generated $2.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) had $272.7M in total assets as of fiscal year 2025, including both current and long-term assets.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) invested $1.7M in research and development during fiscal year 2025.
Yes, XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) spent $16.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) had a current ratio of 3.37 as of fiscal year 2025, which is generally considered healthy.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) had a debt-to-equity ratio of 1.15 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) had a liabilities-to-equity ratio of 2.01 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) had a return on assets of 11.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) has an earnings quality ratio of 0.09x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) has an interest coverage ratio of 0.87x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.